Actively Recruiting
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
Led by Shanghai Jiao Tong University School of Medicine · Updated on 2025-02-18
30
Participants Needed
5
Research Sites
137 weeks
Total Duration
On this page
Sponsors
S
Shanghai Jiao Tong University School of Medicine
Lead Sponsor
S
Shanghai Clinical Research Center
Collaborating Sponsor
AI-Summary
What this Trial Is About
Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment. In our pre-clinical study, we found that targeting histone deacetylase inhibitor 3 (HDAC3)degraded PML-RARa oncoprotein and induced differentiation and apoptosis of RA and As resistant APL in vitro and in vivo. In this study, we evaluate the efficacy and feasibility of combination therapy for HDAC3 inhibitor and venetoclax in patients with refractory APL.
CONDITIONS
Official Title
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with PML-RARb1 positive acute promyelocytic leukemia
- Patients not in remission after treatment with retinoic acid combined with arsenic
- Patients with life expectancy of 3 months or more
- Patients who have provided informed consent
You will not qualify if you...
- Patients with uncontrollable infection
- Patients with life expectancy less than 2 months
- Patients with liver or kidney function abnormalities greater than 3 times normal
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 5 locations
1
The Affiliated Huai An No 1 Perople's Hospital of NanJing University
Huai'an, Jiangsu, China
Not Yet Recruiting
2
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Not Yet Recruiting
3
Jiong HU
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
4
Zhaxin Hospital, Go Broad Health Care
Shanghai, Shanghai Municipality, China
Active, Not Recruiting
5
NanFang Hospital
Guangzhou, China
Actively Recruiting
Research Team
C
Chun Wang, M.D.,
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here